Pulmonary Fibrosis Foundation Scholar receives NIH award
The Pulmonary Fibrosis Foundation reports that 2019 PFF Scholar, Dr. Jeremy Katzen has received a National Institutes of Health K08 award.
Category: Pulmonary Fibrosis
Pulmonary Fibrosis
Latest
Pulmonary Fibrosis
Latest
IPF: Stem Cells from Placental Amniotic Membrane Slow Lung Scarring
Stem cells collected from human amniotic membrane (one of the two fetal membranes forming the amniotic sac) can slow the progression of scarring in pulmonary fibrosis.
Pulmonary Fibrosis
Popular
Country Music Artist Joe Nichols Raising Awareness of IPF
Country music artist Joe Nichols is partnering with Boehringer Ingelheim Pharmaceuticals to raise awareness of idiopathic pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis Drugs Increase Longevity, Decrease Hospitalizations
Pulmonary fibrosis drugs pirfenidone and nintedanib appear to increase longevity and decrease hospitalizations in IPF patients.
Read More
Occupational Hazards Account for More Than One in Ten People with Range of Lung Diseases
More than 1 in 10 people with a range of non-cancerous lung diseases may be sick as a result of...
Read More
PFF Patient Registry Research Generates 23 Studies
To date, 23 studies, including abstracts and manuscripts, have been developed or are underway using data from the Pulmonary Fibrosis Foundation Patient Registry.
Read More
Drug Reduced FVC Decline in Pulmonary Fibrosis Patients
A clinical study of patients with idiopathic pulmonary fibrosis treated with PRM-151 demonstrated the drug had a sustained benefit on 6-minute walking distance and on reducing FVC decline.
Read More
Trial to Test Therapy for Persistent Cough in Pulmonary Fibrosis
Respivant Sciences has dosed the first patient in the SCENIC trial, a Phase 2b study of RVT-1601 for the treatment of persistent cough in patients with idiopathic pulmonary fibrosis (IPF).
Read More
PF Foundation Reaffirms Caution Over Stem Cell Therapies for PF
The Pulmonary Fibrosis Foundation strongly cautions patients with PF against using stem cell treatments outside of an approved clinical trial.
Read More
Idiopathic Pulmonary Fibrosis Diagnostic Gets Medicare Coverage
Veracyte Inc has received a final Medicare local coverage determination (LCD) for the Envisia Genomic Classifier, a genomic diagnostic for idiopathic pulmonary fibrosis (IPF).
Read More
Mutation Prevents Mucus Clearance in Small Airways
Investigators have identified a connection between mucus in the small airways and pulmonary fibrosis.
Read More
New Resource for Pulmonary Fibrosis Patients
Responsum for PF is a free service that allows patients to easily access trusted, comprehensive, and understandable content for pulmonary fibrosis patients, families and caregivers.
Read More
Interstitial Lung Disease: Gram-negative Bacteria Increases Mortality, ICU Admission
The presence of gram-negative bacteria was a risk factor for worse outcomes including higher mortality, ICU admission and vasopressor use in hospitalized patients with interstitial lung diseases.
Read More
New Pharma Company Will Develop IPF Drug
A new biopharmaceutical company called Respivant Sciences has been launched to develop an investigational drug for symptoms of idiopathic pulmonary fibrosis.
Read More
New Diagnostic Guideline for Idiopathic Pulmonary Fibrosis
The ATS, ERS, Japanese Respiratory Society and Latin American Thoracic Society have issued a new international guideline to help physicians diagnosis idiopathic pulmonary fibrosis (IPF).
Read More